间断性大量饮酒对脂肪性肝病命名的影响:全国横断面研究
该研究基于2017-2023年NHANES数据,纳入8006名成人,评估间断性大量饮酒在SLD亚类中的分布及其与肝纤维化的关联。结果显示,MASLD患者中15.9%存在间断性大量饮酒,与显著和晚期肝纤维化风险升高相关(aOR分别为1.69和2.76)。若将此类患者重新分类为MetALD,MetALD的加权患病率将增加一倍以上。
要点
- MASLD患者中15.9%存在间断性大量饮酒。
- 间断性大量饮酒与显著肝纤维化风险升高相关(aOR 1.69)。
- 间断性大量饮酒与晚期肝纤维化风险升高相关(aOR 2.76)。
核心结论
- 间断性大量饮酒在MASLD中普遍存在,且与晚期肝纤维化风险升高约3倍相关。
- 将此类患者重新分类为MetALD可使MetALD的估计患病率增加一倍以上。
研究设计与样本
- 研究为全国横断面研究,使用2017-2023年NHANES数据。
- 纳入8006名有振动控制瞬时弹性成像数据的成人。
- 显著和晚期肝纤维化定义为肝硬度≥8和≥12 kPa。
- 间断性大量饮酒定义为女性任何一天≥4杯、男性≥5杯,且每月至少一次。
- 采用多变量逻辑回归分析,调整年龄、性别和平均酒精消耗量。
主要发现
- 在4571名SLD患者中,3969名为MASLD,373名为MetALD,144名为ALD。
- MASLD患者中632名(15.9%)存在间断性大量饮酒。
- 间断性大量饮酒与显著肝纤维化相关(aOR 1.69;95%CI 1.11-2.58)。
- 间断性大量饮酒与晚期肝纤维化相关(aOR 2.76;95%CI 1.58-4.80)。
- MASLD伴间断性大量饮酒者的显著肝纤维化调整加权患病率为23.6%(95%CI 17.6%-29.6%),高于不伴者的15.6%(95%CI 13.5%-17.6%)。
临床怎么用
- 在评估MASLD患者时,应询问间断性大量饮酒史以识别肝纤维化高风险个体。
- 考虑将间断性大量饮酒的MASLD患者重新分类为MetALD,以更准确反映疾病负担。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Federal agencies define heavy drinking by average increased or episodic heavy alcohol consumption, yet steatotic liver disease (SLD) nomenclature only captures average alcohol consumption to define subcategories. We evaluated episodic heavy drinking among SLD subcategories and its association with liver fibrosis. METHODS: We utilized the 2017-2023 National Health and Nutrition Examination Survey (NHANES) including adults with vibration-controlled transient elastography data. Significant and advanced liver fibrosis were liver stiffness ≥8 and ≥12 kPa. Episodic heavy drinking was ≥4 drinks (women) and ≥5 (men) on any day, at least once per month. Multivariable logistic regression (adjusted for age, sex, average alcohol consumption) analyzed the association of episodic heavy drinking with liver fibrosis in SLD groups. RESULTS: Among 8006 individuals, 4571 had SLD: 3969 had metabolic dysfunction-associated steatotic liver disease (MASLD), 373 had metabolic and alcohol-associated liver disease (MetALD), and 144 had alcohol-associated liver disease (ALD). Among patients with MASLD, 632 (15.9%) had episodic heavy drinking, which was associated with significant (adjusted odds ratio, 1.69; 95% confidence interval [CI], 1.11-2.58) and advanced (adjusted odds ratio, 2.76; 95% CI, 1.58-4.80) liver fibrosis. Adjusted weighted-prevalence of significant liver fibrosis among MASLD with episodic heavy drinking (23.6%; 95% CI, 17.6%-29.6%) was higher than MASLD without episodic heavy drinking (15.6%; 95% CI, 13.5%-17.6%]). Subgroup prevalence using consensus nomenclature vs including episodic heavy drinking as MetALD or ALD decreased the weighted prevalence of MASLD (48.0%; 95% CI, 46.0%-50.0% to 40.4%; 95% CI, 38.5%-42.4%), increased MetALD (5.3%; 95% CI, 4.6%-6.1% to 12.9%; 95% CI, 11.9%-13.9%), whereas ALD was similar (1.9%; 95% CI, 1.5%-2.3% to 2.1%; 95% CI, 1.7%-2.5%). CONCLUSIONS: Episodic heavy drinking is prevalent in MASLD and associated with 3-fold higher odds of advanced liver fibrosis. Reclassifying these patients to MetALD would more than double the estimated prevalence of MetALD.
引用
- Su Y, Dodge JL, Lee BP, et al. Episodic Heavy Drinking and Implications for Steatotic Liver Disease Nomenclature: A National Cross-Sectional Study. Clin Gastroenterol Hepatol. 2026. PMID: 41935595. doi:10.1016/j.cgh.2026.03.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。